Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.595
-0.075 (-2.81%)
Dec 15, 2025, 2:53 PM EST - Market open
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $209.00K in the quarter ending September 30, 2025, a decrease of -43.36%. This brings the company's revenue in the last twelve months to $1.08M, down -30.96% year-over-year. In the year 2024, Perspective Therapeutics had annual revenue of $1.45M with 1.39% growth.
Revenue (ttm)
$1.08M
Revenue Growth
-30.96%
P/S Ratio
181.15
Revenue / Employee
$7,679
Employees
140
Market Cap
192.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | - | - |
| Dec 31, 2022 | - | - | - |
| Sep 30, 2022 | 10.80M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
| Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
| Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
| Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
| Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
| Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
| Jun 30, 2014 | 4.22M | -306.08K | -6.76% |
| Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
| Jun 30, 2012 | 5.07M | -167.89K | -3.20% |
| Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
| Jun 30, 2010 | 5.29M | -131.73K | -2.43% |
| Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
| Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
| Jun 30, 2007 | 5.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CATX News
- 25 days ago - Perspective Therapeutics to Participate in Upcoming December Conferences - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics to Participate in Upcoming November Conferences - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript - Seeking Alpha
- 2 months ago - Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 - GlobeNewsWire
- 3 months ago - Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors - GlobeNewsWire